Torben Lykke Sørensen

Torben Lykke Sørensen

Auto-generated profile, based on publicly available information

Torben Lykke Sørensen

Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
TSTorben L. Sørensen
Torben L. Sørensen
CTCorinna Trebst
Corinna Trebst
PKPia Kivisäkk
Pia Kivisäkk
KKKaren L. Klaege
Karen L. Klaege
AMAmit Majmudar
Amit Majmudar
FSFinn Sellebjerg
Finn Sellebjerg

1 May 2020 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
MRMaarten P. Rozing
Maarten P. Rozing
JDJon A. Durhuus
Jon A. Durhuus
MNMarie Krogh Nielsen
Marie Krogh Nielsen
Yousif SubhiYousif Subhi
Yousif Subhi
TKThomas Bl. Kirkwood
Thomas Bl. Kirkwood
TSTorben Lykke Sørensen
Torben Lykke Sørensen

14 November 2001 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
TST. L. Sørensen
T. L. Sørensen
FSF. Sellebjerg
F. Sellebjerg
CJC. V. Jensen
C. V. Jensen
RSR. M. Strieter
R. M. Strieter
RRR. M. Ransohoff
R. M. Ransohoff

1 July 2004 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
TST. L. Sørensen
T. L. Sørensen
RRR. M. Ransohoff
R. M. Ransohoff
RSR. M. Strieter
R. M. Strieter
FSF. Sellebjerg
F. Sellebjerg

23 October 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
TSTorben L. Sørensen
Torben L. Sørensen
FSFinn Sellebjerg
Finn Sellebjerg
Background: Chemokines, small chemotactic cytokines, have been implicated in active relapsing-remitting MS (RRMS). However, the role of chemokines and chemokine receptors has not been specifically studied in secondary progressive MS (SPMS). Methods: Fifteen patients with SPMS, 15 patients with relapses of RRMS, 10 patients with RRMS in remission, and 20 healthy controls were included in this study. The expression of CC chemokine receptor 1(CCR1), CCR2, CCR3, CCR5, and CXC chemokine receptor 3(CXCR3) was studied on leukocyte subsets using flow cytometry, and the cytokine profile of T cells expressing CCR2 and CCR5 was determined. The authors also studied the effect of treatment with interferon-β-1b on the expression of chemokine receptors in SPMS. Results: The authors found a significantly higher percentage of CCR2-expressing T cells in SPMS than in the other patients groups. CCR2-positive T cells produced high levels of interleukin (IL)-5 and low levels of tumor necrosis factor α, indicating a T-helper type 2 (Th2)/T-cytotoxic type 2 (Tc2) profile of these cells. The expression of CCR5, a chemokine receptor associated with Th1 responses, was significantly lower in SPMS than in patients with active RRMS. Interferon (IFN) β-1b treatment in SPMS did not alter chemokine receptor expression in SPMS. Conclusion: The authors find qualitative differences in the systemic inflammatory response in RRMS and SPMS, indicating a distinct inflammatory environment in SPMS. Chemokine receptor expression in SPMS did not change after treatment with IFNβ-1b. It remains to be established if these findings reflect differences between RRMS and SPMS in effector or regulatory mechanisms.

4 June 2017 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
Yousif SubhiYousif Subhi
Yousif Subhi
TSTorben Lykke Sørensen
Torben Lykke Sørensen
Purpose. To investigate neovascular age-related macular degeneration (AMD) in patients aged ≥90 years from several perspectives for a comprehensive overview: prevalence, presenting characteristics, treatment adherence, reasons for discontinuation, and efficacy of antivascular endothelial growth factor (VEGF) treatment comparing Ranibizumab and Aflibercept.Methods. In this retrospective chart review, we determined the prevalence and presenting characteristics by reviewing all data for patients referred to our department with treatment-naïve neovascular AMD. By looking at historical cohorts, we determined adherence to treatment, reasons for discontinuation, and treatment outcomes after loading dose, 12 months, and 24 months.Results. Patients aged ≥90 years constituted 7% of the patients. Treatment was discontinued in 51%, primarily because of death and treatment burden. Mean change in best-corrected visual acuity was 3.2, 1.5, and −2.2 ETDRS letters at 4, 12, and 24 months, respectively. Aflibercept was superior to Ranibizumab in visual and anatomic outcomes. After two years of treatment, patients losing ≥15 ETDRS letters made up 19% in the Aflibercept group and 26% in the Ranibizumab group.Conclusions. We propose that the very old patients with neovascular AMD may constitute a distinctive group warranting special attention and possibilities for individualized therapy. Possible differences between anti-VEGF agents need further investigations.